NextCure, Inc. (NASDAQ:NXTC – Get Free Report) was the target of a significant growth in short interest in March. As of March 15th, there was short interest totalling 839,700 shares, a growth of 579.9% from the February 29th total of 123,500 shares. Based on an average trading volume of 229,500 shares, the short-interest ratio is […]
NextCure (NASDAQ:NXTC – Free Report) had its price target boosted by HC Wainwright from $5.00 to $8.00 in a research note released on Friday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. Separately, Needham & Company LLC reissued a buy rating and issued a $4.00 target price on shares of NextCure […]
NextCure, Inc. (NASDAQ:NXTC – Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 108,900 shares, a decrease of 11.8% from the January 15th total of 123,400 shares. Based on an average daily volume of 91,000 shares, the […]
NextCure, Inc. (NASDAQ:NXTC – Get Free Report)’s stock price dropped 1.1% during trading on Monday . The stock traded as low as $1.30 and last traded at $1.34. Approximately 117,807 shares traded hands during trading, an increase of 79% from the average daily volume of 65,754 shares. The stock had previously closed at $1.35. NextCure […]
NextCure (NASDAQ:NXTC – Get Free Report) and NGM Biopharmaceuticals (NASDAQ:NGM – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings. Insider & Institutional Ownership 47.8% of NextCure shares […]